Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2014
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium
Danelle F James, Lillian Werner, Jennifer R Brown, et al.
Hematology/Oncology and Stem Cell Therapy
|
October 18, 2020
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
Megan Melody, Zaid Abdel Rahman, Hollie Saunders, et al.
Advances in Hematology
|
February 1, 2022
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
Januario E Castro, Paula A Lengerke-Diaz, Juliana Velez Lujan, et al.
Hematology (Amsterdam, Netherlands)
|
July 8, 2022
Extracorporeal photopheresis for the treatment of chronic graft versus host disease
Emin Kansu, David Ward, Amber P Sanchez, et al.
Cell Stem Cell
|
June 3, 2018
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Michael Y Choi, George F Widhopf, Emanuela M Ghia, et al.
Oncotarget
|
December 10, 2015
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
Manoj K Kashyap, Deepak Kumar, Harrison Jones, et al.
Journal of Hematology & Oncology
|
May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Leukemia & Lymphoma
|
February 3, 2022
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience
Megan Melody, Sangeetha Gandhi, Hollie Saunders, et al.
Molecular Therapy. Nucleic Acids
|
June 7, 2024
Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia
Manoj Kumar Kashyap, Hiren Karathia, Deepak Kumar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 24, 2016
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2014
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium
Danelle F James, Lillian Werner, Jennifer R Brown, et al.
Hematology/Oncology and Stem Cell Therapy
|
October 18, 2020
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
Megan Melody, Zaid Abdel Rahman, Hollie Saunders, et al.
Advances in Hematology
|
February 1, 2022
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576
Januario E Castro, Paula A Lengerke-Diaz, Juliana Velez Lujan, et al.
Hematology (Amsterdam, Netherlands)
|
July 8, 2022
Extracorporeal photopheresis for the treatment of chronic graft versus host disease
Emin Kansu, David Ward, Amber P Sanchez, et al.
Cell Stem Cell
|
June 3, 2018
Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Michael Y Choi, George F Widhopf, Emanuela M Ghia, et al.
Oncotarget
|
December 10, 2015
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway
Manoj K Kashyap, Deepak Kumar, Harrison Jones, et al.
Journal of Hematology & Oncology
|
May 21, 2017
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia
Manoj K Kashyap, Carlos I Amaya-Chanaga, Deepak Kumar, et al.
Leukemia & Lymphoma
|
February 3, 2022
Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience
Megan Melody, Sangeetha Gandhi, Hollie Saunders, et al.
Molecular Therapy. Nucleic Acids
|
June 7, 2024
Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia
Manoj Kumar Kashyap, Hiren Karathia, Deepak Kumar, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
September 24, 2016
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Mohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, et al.
Page
of 5